button bars forest bayes pooled summary circles
 
deaths (OS)

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus capecitabine
atezolizumab plus bevacizumab vs. capecitabine 1 certainty unassessable-6%
versus regorafenib
atezolizumab alone vs. regorafenib 1 certainty unassessable0%
atezolizumab plus cometinib vs. regorafenib 1 certainty unassessable0%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons